Author Profile

Written By

Manuel Guzman

President, CAS

Manuel Guzman is the President of CAS, a division of the American Chemical Society that specializes in scientific information solutions. Since joining CAS in 2013, Manuel has been responsible for driving innovative business and solutions strategies focused on maximizing the value of CAS content, technology, and expertise to accelerate scientific discovery. Prior to his time at CAS, Manuel held various executive positions within the information industry including EVP of Learning, Research Solutions & International for Cengage Learning; President and CFO of Thomson Learning's Career & Professional Group; and co-founder and CEO of Monument Information Resource/MIR Management Corporation. Manuel has a B.S. in accounting and an MBA in Finance from Seton Hall.

Latest Content from Manuel Guzman

Parachutists showing the value of connected partnership

January 4, 2022

Designing for agility in the connected innovation ecosystem

CAS President Manny Guzman shares his thoughts on the importance of connections and partnerships in the innovation and discovery process.

Hero image for Real World Collaboration blog

July 15, 2021

Real World Collaboration: Accelerating Scientific Innovation in an Evolving World

Though we often think of scientific discovery as being driven by competition, going forward, one of the key questions is how we can achieve the optimal balance between collaboration and competition to enhance scientific innovation.

CAS rebrand evolution image

May 6, 2021

Our evolution is a job that is never done

The work of scientific discovery is never done but is continuously improving, and such is also the case for CAS.

January 5, 2021

Optimizing our “new normal” to achieve exceptional innovation in 2021 and beyond

April 9, 2020

In This Together: CAS Joining Forces with Researchers and Data Scientists to Accelerate COVID-19 Treatments

With millions of confirmed COVID-19 cases, and many more likely going untested, researchers around the world are racing to find solutions to this daunting challenge. Approved drugs are being explored as treatments for those afflicted, vaccines to prevent the long-term spread are in development, as well as many other efforts beyond drug discovery. To keep frontline healthcare professionals safe, manufacturers are reimagining production processes to make critical supplies, such as hand sanitizer and mask filters, testing methods are being optimized to be faster and more accurate, materials for new germ-resistant masks are being developed and new systems to sterilize medical equipment are being designed.

January 10, 2020

Three strategic imperatives for the next decade of scientific innovation

January 25, 2019

From T to key: The changing shape of today's innovation workforce

While there will always be need for I- and T-shaped professionals, most professionals today can't count on being really good at one thing to succeed. Organizations are increasingly seeking key-shaped candidates when recruiting new talent. So, how can individuals and organizations across industries become more key-shaped?

October 19, 2018

Digital disruption in drug discovery: Perspectives from industry experts

At CAS, we strive to help organizations leverage the right content and technology, in combination with human expertise, to access mission-critical scientific data that drives discovery and informs strategic investment decisions. So, I was eager to hear the panelists' perspectives on both the positive and challenging aspects of expanding technology into the drug development process. As I listened to the conversation, I found myself nodding in agreement. Many of the points they discussed are challenges we at CAS work to solve every day.

September 21, 2018

A looming global intellectual property crisis: Is your organization at risk?

With the growing importance of intellectual property as part of an organization's business strategy, the efficiency of the world's patent offices can have a significant impact on your roadmap—and your bottom line. Reducing pendency on global patent filings is critical for commercial organizations that need to innovate and protect their intellectual property, as well as patent offices that are struggling with a backlog of patents resulting from increases in applications around the world.